U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C11H17NO3.ClH
Molecular Weight 247.7189
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOPROTERENOL HYDROCHLORIDE

SMILES

CC(C)NCC(c1ccc(c(c1)O)O)O.Cl

InChI

InChIKey=IROWCYIEJAOFOW-UHFFFAOYSA-N
InChI=1S/C11H17NO3.ClH/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8;/h3-5,7,11-15H,6H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula C11H17NO3
Molecular Weight 211.258
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/cdi/isoproterenol.html | https://www.ncbi.nlm.nih.gov/pubmed/209581 | https://www.ncbi.nlm.nih.gov/pubmed/22073124 | https://www.ncbi.nlm.nih.gov/pubmed/11723224

Isoproterenol (trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. Isoproterenol is a non-selective β adrenoreceptor agonist and TAAR1 agonist that is the isopropylaminomethyl analog of epinephrine. Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2 adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptors' vasodilation. The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce tachycardia (an elevated heart rate), which predisposes patients to cardiac arrhythmias.

Originator

Sources: Archiv fuer Experimentelle Pathologie und Pharmakologie, Volume 197, Pages 41-56, Journal, 1940

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
42 ng/mL
0.3 mg/kg single, subcutaneous
dose: 0.3 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ISOPROTERENOL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Other AEs: Tachycardia, Premature ventricular contractions...
Other AEs:
Tachycardia (66.7%)
Premature ventricular contractions (8.3%)
Sources: Page: p.642
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources: Page: p.2
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Tachycardia 66.7%
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Premature ventricular contractions 8.3%
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Adams-Stokes syndrome Disc. AE
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Block heart Disc. AE
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Adams-Stokes syndrome Disc. AE
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Block heart Disc. AE
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Myocardial DNA and cell count following isoproterenol-induced myocardial necrosis in the rat].
1975
Method for the production of severe ventricular dysrhythmias in small laboratory animals.
1975
Membrane phospholipid metabolism in the isoproterenol-induced cardiomyopathy of the rat.
1975
Metabolic response after isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs nonarteriosclerotic virgin intact and gonadectomized male rats.
1975 Apr
Serum prolactin levels in rats following isoproterenol-induced myocardial infarction.
1975 Dec
[Pharmacology of acebutolol in animals].
1975 Dec 31
Prolyl hydroxylase and collagen metabolism after experimental mycardial infarction.
1975 Jan
Effects of prindolol on isoproterenol-induced subendocardial ischaemia in dogs with multiple chronic coronary artery occlusion.
1975 Jul
The use of practolol in supraventricular arrhythmias associated with acute illnesses.
1975 May
Metabolic responses following isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs. non-arteriosclerotic virgin and ovariectomized female rats.
1975 May-Jun
[Prevention of isoproterenol-induced lesions in the rat myocardium by prenylamine].
1975 Sep-Oct
Decreased SOD activity and increased nitrates level in rat heart with left ventricular hypertrophy induced by isoproterenol.
1999 Jul-Dec
Recurrent asystoles associated with vasovagal reaction during venipuncture.
2000 Dec
Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties.
2000 Jun
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].
2000 Nov
Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system.
2001 Apr
Elevated parasympathetic nerve tone in isoproterenol-induced neurally mediated syncope during head-up tilt testing.
2001 Apr
A comparison of effects measured with isotonic and isometric recording: II. Concentration-effect curves for physiological antagonists.
2001 Aug
Effects of alpha- and beta-adrenergic stimulation on free magnesium concentrations in platelets from healthy and obese individuals.
2001 Dec
Differential effects of atropine and isoproterenol on inducibility of atrioventricular nodal reentrant tachycardia.
2001 Dec
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
2001 Dec
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
2001 Feb
Paroxysmal tachycardia in children and teenagers with normal sinus rhythm and without heart disease.
2001 Jan
Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells.
2001 Jan
beta(1)-Adrenoceptors compensate for beta(3)-adrenoceptors in ileum from beta(3)-adrenoceptor knock-out mice.
2001 Jan
Interaction of calcitonin gene-related peptide (CGRP), substance P (SP) and conventional autonomic agonists in rat submandibular salivary peroxidase release in vitro.
2001 Jan 14
cAMP mediated upregulation of CYP2A5 in mouse hepatocytes.
2001 Jan 26
Activation of mitochondrial oxidative phosphorylation during (+/-)-isoproterenol-induced cell injury of myocardium.
2001 Jan-Mar
[Functional characterization of myocardial hypertrophy induced by isoproterenol and its regression].
2001 Jul
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.
2001 Jul
A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities.
2001 Jul
Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts.
2001 Jul
Alterative and plastic insufficiency of cardiomyocytes: isoproterenol-induced damage to myocardium during anthracycline cardiomyopathy.
2001 Jun
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001 Mar
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
2001 Mar 13
Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal.
2001 Mar 2
Cardioprotective effects of Picrorrhiza kurroa against isoproterenol-induced myocardial stress in rats.
2001 May
PKC-beta is not necessary for cardiac hypertrophy.
2001 May
In vitro activity of polyhydroxycarboxylates against herpesviruses and HIV.
2001 Nov
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
2001 Oct
Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes.
2001 Sep 14
Impaired intracellular signal transduction via cyclic AMP contributes to cerebral vasospasm in rats with subarachnoid hemorrhage.
2002 Apr
Expression of human angiotensinogen-renin in rat: effects on transcription and heart function.
2002 Feb
The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation.
2002 Feb
Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats.
2002 Feb
99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.
2002 Feb 21
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats.
2002 Jan
Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors.
2002 Jan 22
Glucose uptake via SGLT-1 is stimulated by beta(2)-adrenoceptors in the ruminal epithelium of sheep.
2002 Jun
Vanillylamide-based propanolamine derivative displays alpha/beta-adrenoceptor blocking and vasodilating properties.
2002 Jun
Patents

Sample Use Guides

Bolus intravenous injection: 0.02 mg to 0.06 mg; Intravenous infusion: 5 mcg/min; Intramuscular 0.2 mg; Subcutaneous 0.2 mg; Intracardiac 0.02 mg;
Route of Administration: Other
Human embryonic kidney cells (HEK293) were cultured in Minimum Essential Medium (MEM) Earle’s (Biochrom AG) supplemented with 10% FBS (PAA Laboratories GmbH), 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom AG) and 2 mM L-glutamine (Invitrogen) at 37C with 5% CO2. 48 well plates were coated with Poly-L-Lysine (Biochrom) and HEK293 cells were seeded with 37,500 cells per well. Transient transfection in triplicates with 84 ng DNA/well using metafectene according to manufactures instructions (Biontex, Munich, Germany) was performed 28 hours later. 40 hours after transfection cells were pre-incubated for 5 minutes with stimulation buffer containing of MEM Earle’s media and 1 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma). This stimulation buffer was used for all further steps. For ligand competition experiments cells were incubated with tyramine, 2-phenylethylamine or octopamine ranging from 6.7 nM to 6700 nM, diluted in stimulation buffer for 15 minutes followed by a stimulation with isoprenaline in concentrations ranging from 1 nM to 10000 nM for 30 minutes. All reactions were performed at 37C with 5% CO2 saturated air and stopped by aspirating medium.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:44 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:44 UTC 2021
Record UNII
DIA2A74855
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOPROTERENOL HYDROCHLORIDE
ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
ISOPRENALINE HYDROCHLORIDE [WHO-IP]
Common Name English
ISOMENYL
Brand Name English
NSC-37745
Code English
1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-, HYDROCHLORIDE
Systematic Name English
ISOPROTERENOL HYDROCHLORIDE COMPONENT OF DUO-MEDIHALER
Common Name English
ISUPREL
Brand Name English
MISTAREL
Brand Name English
ISOPRENALINE HYDROCHLORIDE [EP]
Common Name English
ISOPRENALINE HYDROCHLORIDE
EP   MART.   WHO-DD   WHO-IP  
Common Name English
ISOPRENALINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
ISOPRENALINE HYDROCHLORIDE [WHO-DD]
Common Name English
ISOPRENALINE HYDROCHLORIDE [MART.]
Common Name English
3,4-DIHYDROXY-.ALPHA.-((ISOPROPYLAMINO)METHYL)BENZYL ALCOHOL HYDROCHLORIDE
Systematic Name English
ISOPROTERENOL HYDROCHLORIDE [USP-RS]
Common Name English
ISOPROTERENOL HYDROCHLORIDE [ORANGE BOOK]
Common Name English
AEROLONE
Brand Name English
EUSPIRAN
Brand Name English
ISOPROTERENOL HYDROCHLORIDE [VANDF]
Common Name English
NORISODRINE AEROTROL
Brand Name English
ISOPRENALINE HYDROCHLORIDE, DL-
Common Name English
ISOPROTERENOL HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
DL-ISOPRENALINE HYDROCHLORIDE
JAN  
Common Name English
SUSCARDIA
Brand Name English
AEROTROL
Brand Name English
ISOPROTERENOL HCL
Common Name English
VAPO-ISO
Brand Name English
ISOPROTERENOL DL-FORM HYDROCHLORIDE [MI]
Common Name English
ISOVON
Brand Name English
DL-ISOPRENALINE HYDROCHLORIDE [JAN]
Common Name English
DUO-MEDIHALER COMPONENT ISOPROTERENOL HYDROCHLORIDE
Common Name English
NSC-89747
Code English
Classification Tree Code System Code
NCI_THESAURUS C319
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
Code System Code Type Description
PUBCHEM
5807
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
FDA UNII
DIA2A74855
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
CAS
71249-42-8
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
SUPERSEDED
DRUG BANK
DBSALT000429
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
USP_CATALOG
1351005
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C29133
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-089-8
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
CAS
51-30-9
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
CAS
1336-89-6
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
SUPERSEDED
MERCK INDEX
M6533
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY Merck Index
EVMPD
SUB02794MIG
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
CAS
949-36-0
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
SUPERSEDED
WHO INTERNATIONAL PHARMACOPEIA
ISOPROTERENOL HYDROCHLORIDE
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Freely soluble in water; sparingly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Bronchodilator. Storage: Isoprenaline hydrochloride should be kept in a tightly closed container, protected from light.Additional information: Isoprenaline hydrochloride gradually darkens in colour on exposure to air and light. Even in the absence of light, Isoprenaline hydrochloride is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Isoprenaline hydrochloride contains not less than 97.5% and not more than 101.0% of C11H17NO3,HCl, calculated with reference to the dried substance.
RXCUI
82030
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY RxNorm
EPA CompTox
51-30-9
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
ECHA (EC/EINECS)
213-438-4
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
ALTERNATIVE
ChEMBL
CHEMBL434
Created by admin on Fri Jun 25 20:54:44 UTC 2021 , Edited by admin on Fri Jun 25 20:54:44 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY